The common age of these patients was 63. Almost 40 % of the men were African-American. Fifty-six % experienced at least a university education level. Despite being known for biopsy because they were regarded as at increased risk for prostate cancer, usually because of a blood test, 55 % of the African-American men during prostate biopsy said they had a zero % potential for having prostate cancer . Only 20 % of the Caucasian men said this. Related StoriesNew findings reveal association between colorectal cancer tumor and melanoma medication treatmentCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesSausages With Antioxidants From Berries TO AVOID CancerOf the African-American guys in the clinics whose biopsy outcomes were available to the researchers, 70 % were subsequently diagnosed with prostate cancer .Clinical research of the device for this function demonstrated people treated with the Optune/drug combination lived typically three months much longer than those treated with the drug alone. ‘Patients newly diagnosed with this challenging and aggressive type of brain cancer now have another treatment option available,’ stated Dr. William Maisel, acting director of any office of Gadget Evaluation in the FDA’s Center for Products and Radiological Health. ‘While the treatment is not really a cure, it can increase survival by almost a year.’ Brain and nervous system cancers will end up being diagnosed in an estimated 23, 000 Americans this whole year, killing more than 15,000, the FDA said, citing the U.S.